Back
Results - Announcements
Transgene Biotek Ltd consolidated sales up 20% on year in Q2FY2026
07-Aug-2026, 01:33
Transgene Biotek Ltd share price softened by 1.36% to Rs 2.91 after the company's net profit fell 15.22% to Rs 0.39 crore, while revenue from operations increased sharply by 20% to Rs 0.06 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 73444.53 crore, easing 8.17%. It has marginally improved by 0.70% over last one week and advanced by 12.28% in last one month while the market capitalization of Transgene Biotek Ltd has slipped by 3.33% and 6.13% in the same period respectively. Profit before tax (PBT) of Transgene Biotek Ltd stood at Rs 0.39 crore in Q2 FY26, slipping 9.30% year-on-year, and tumbling by 15.22% quarter-on-quarter. EBITDA came in at Rs 0 crore, tanking 57.14% YoY and nosediving by 86.05% sequentially. Total expenses tumbled by 57.89% to Rs 0.16 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.03 crore, remaining flat YoY. For the TTM ended FY26, revenue from operations improved 13.04% to Rs 0.26 crore, while net profit inched up 3.03% to Rs 0.68 crore, compared to previous TTM. EBITDA plunged by 180% to Rs 1.91 crore, and PBT saw a minor gain of 3.03% to Rs 0.68 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1.2 crore in FY26, as against Rs 0.0 crore in FY25. Transgene Biotek Ltd crashed 39.12% in last one year, underperforming the benchmark BSE Sensex which has eased by 1.97% during the same period.
Transgene Biotek Ltd share price softened by 1.36% to Rs 2.91 after the company's net profit fell 15.22% to Rs 0.39 crore, while revenue from operations increased sharply by 20% to Rs 0.06 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 73444.53 crore, easing 8.17%. It has marginally improved by 0.70% over last one week and advanced by 12.28% in last one month while the market capitalization of Transgene Biotek Ltd has slipped by 3.33% and 6.13% in the same period respectively. Profit before tax (PBT) of Transgene Biotek Ltd stood at Rs 0.39 crore in Q2 FY26, slipping 9.30% year-on-year, and tumbling by 15.22% quarter-on-quarter. EBITDA came in at Rs 0 crore, tanking 57.14% YoY and nosediving by 86.05% sequentially. Total expenses tumbled by 57.89% to Rs 0.16 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 0.03 crore, remaining flat YoY. For the TTM ended FY26, revenue from operations improved 13.04% to Rs 0.26 crore, while net profit inched up 3.03% to Rs 0.68 crore, compared to previous TTM. EBITDA plunged by 180% to Rs 1.91 crore, and PBT saw a minor gain of 3.03% to Rs 0.68 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1.2 crore in FY26, as against Rs 0.0 crore in FY25. Transgene Biotek Ltd crashed 39.12% in last one year, underperforming the benchmark BSE Sensex which has eased by 1.97% during the same period.